Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus
II. Fenugreek (Trigonella foenum-graecum)
Authors:
David Koupý; Hana Kotolová; Jana Rudá Kučerová
Authors‘ workplace:
Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta
; Ústav humánní farmakologie a toxikologie, Brno
; Vojenská nemocnice Brno, Interní oddělení, Brno
Published in:
Čes. slov. Farm., 2015; 64, 67-71
Category:
Review Articles
Overview
Fenugreek seeds are known for their characteristic smell of soup seasoning and as an ingredient of Indian curry. Traditionally the seeds are used as macerate for the treatment of diabetes, cough, and flatulence, to increase breast milk secretion, and for anti-inflammatory and aphrodisiac effects. The use is limited by its unpleasant smell and bitter taste which can be modified by adding mint leaves to the macerate. Antidiabetic properties are attributed mainly to galactomannan, 4-hydroxyisoleucin (4-OH-Ile), diosgenin and trigonelline. These substances demonstrate direct antidiabetic properties in clinical studies by increasing insulin secretion (4-OH-Ile), decreasing insulin resistance and glucose resorption from the GIT (galactomannan) and improvement in B-cells regeneration (trigonelline). Besides this main effect, the herb improves blood lipid spectre (4-OH-Ile, diosgenin), and has reno-protective (4-OH-Ile, trigonelline), neuroprotective (trigonelline) and antioxidant (diosgenin, trigonelline) effects. Antidiabetic efficacy of trigonelline is comparable to glibenclamide treatment and more effective than sitagliptine therapy. Given the large body of evidence and promising results in comparison with standard pharmacotherapy, fenugreek active substances have a potential to become a source of new antidiabetic medication.
Key words:
fenugreek • Trigonella foenum-graecum • diabetes mellitus type 2 • biological activity
Sources
1. Mika K. Fytoterapia pre lekárov. Martin: Osveta 1991.
2. Tomko J. Farmakognózia. Martin: Osveta 1999.
3. Assessment report on Trigonella foenum-graecum L., semen, Comittee on Herbal Medicinal Products (HMPC), European Medicines Agency 2010.
4. Srichamroen A., Thomson A. B., Field C. J., Basu T. K. In vitro intestinal glucose uptake is inhibited by galactomannan from Canadian fenugreek seed (Trigonella foenum graecum L) in genetically lean and obese rats. Nutr. Res. 2009; 29, 49–54.
5. Sauvaire Y., Girardon P., Baccou J. C., Risterucci A. M. Changes in growth, proteins and free amino acids of developing seed and pod of fenugreek. Phytochemistry 1984; 23, 479–486.
6. Alcock N. W., Crout D. H. G., Gregorio M. V. M., Lee E., Pike G., Samuel C. J. Stereochemistry of the 4-hydroxyisoleucine from Trigonella foenum-graecum. Phytochemistry 1989; 28, 1835–1841.
7. Broca C., Manteghetti M., Gross R., Baissac Y., Jacob M., Petit P., Sauvaire Y., Ribes G. 4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion. Eur. J. Pharmacol. 2000; 390, 339–345.
8. Sauvaire Y., Petit P., Broca C., Manteghetti M., Baissac Y., Fernandez-Alvarez J., Gross R., Roye M., Leconte A., Gomis R., Ribes G. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes 1998; 47, 206–210.
9. Broca C., Gross R., Petit P., Sauvaire Y., Manteghetti M., Tournier M., Masiello P., Gomis R., Ribes G. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am. J. Physiol. 1999; 277, E617–623.
10. Haeri M. R., Limaki H. K., White C. J., White K. N. Non-insulin dependent anti-diabetic activity of (2S,3R,4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine 2012; 19, 571–574.
11. Raju J., Gupta D., Rao A. R., Yadava P. K., Baquer N. Z. Trigonellafoenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol. Cell. Biochem. 2001; 224, 45–51.
12. Vats V., Yadav S. P., Grover J. K. Effect of T. foenum graecum on glycogen content of tissues and the key enzymes of carbohydrate metabolism. J. Ethnopharmacol. 2003; 85, 237–242.
13. Broca C., Breil V., Cruciani-Guglielmacci C., Manteghetti M., Rouault C., Derouet M., Rizkalla S., Pau B., Petit P., Ribes G., Ktorza A., Gross R., Reach G., Taouis M. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am. J. Physiol. Endocrinol. Metab. 2004; 287, E463–471.
14. Al-Habori M., Raman A., Lawrence M. J., Skett P. In vitro effect of fenugreek extracts on intestinal sodium-dependent glucose uptake and hepatic glycogen phosphorylase A. Int. J. Exp. Diabetes Res. 2001; 2, 91–99.
15. Hannan J. M., Ali L., Rokeya B., Khaleque J., Akhter M., Flatt P. R., Abdel-Wahab Y. H. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br. J. Nutr. 2007; 97, 514–521.
16. Srichamroen A., Thomson A. B., Field C. J., Basu T. K. In vitro intestinal glucose uptake is inhibited by galactomannan from Canadian fenugreek seed (Trigonella foenum graecum L) in genetically lean and obese rats. Nutr. Res. 2009; 29, 49–54.
17. Gopalpura P. B. J. C., Dubey S. Effect of Trigonella foenum-graecum seeds on the glycemic index of food: A clinical evaluation. Int. J. Diab. Dev. Ctries. 2009; 27, 41–45.
18. Kulkarni C. P., Bodhankar S. L., Ghule A. E., Mohan V., Thakurdesai P. A. Antidiabetic activity of Trigonella foenumgraecum L. seeds extract (IND01) in neonatal streptozotocin-induced (n-STZ) rats. Diabetol. Croat. 2012; 41, 29–40.
19. Zhou J., Chan L., Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr. Med. Chem. 2012; 19, 3523–3531.
20. Pari L., Monisha P., Mohamed Jalaludeen A. Beneficial role of diosgenin on oxidative stress in aorta of streptozotocin induced diabetic rats. Eur. J. Pharmacol. 2012; 691, 143–150.
21. Ghule A. E., Jadhav S. S., Bodhankar S. L. Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats. Int. Immunopharmacol. 2012; 14, 740–748.
22. Yoshinari O., Takenake A., Igarashi K. Trigonelline ameliorates oxidative stress in type 2 diabetic goto-kakizaki rats. J. Med. Food 2013; 16, 34–41.
23. Arshadi S., Bakhtiyari S., Haghani K., Valizadeh A. Effects of Fenugreek Seed Extract and Swimming Endurance Training on Plasma Glucose and Cardiac Antioxidant Enzymes Activity in Streptozotocin-induced Diabetic Rats. Osong Public Health Res. Perspect. 2015; 6, 87–93.
24. Sharma S., Mishra V., Jayant S. K., Srivastava N. Effect of Trigonella foenum graecum L on the Activities of Antioxidant Enzyme and Their Expression in Tissues of Alloxan-Induced Diabetic Rats. J. Evid. Based Complementary Altern. Med. 2015; pii: 2156587215573664.
25. Narender T., Puri A., Shweta S., Khaliq T., Saxena R., Bhatia G., Chandra R. 4-hydroxyisoleucine an unusual amino acid as antidyslipidemic and antihyperglycemic agent. Bioorg. Med. Chem. Lett. 2006; 16, 293–296.
26. Sauvaire Y., Ribes G., Baccou J. C., Loubatieeres-Mariani M. M. Implication of steroid saponins and sapogenins in the hypocholesterolemic effect of fenugreek. Lipids 1991; 26, 191–197.
27. Shetty A. K., Salimath P. V. Reno-protective effects of fenugreek (Trigonella foenum greacum) during experimental diabetes. e-SPEN, Eur. e-J. Clin. Nutr. Met. 2009; 4, e137–e142.
28. Nakamura S., Tanigawa K., Kawaguchi M., Inoue Y., Xu G., Nagami H., Teramoto M., Kato Y., Tamura K. Effect of chronic vanadate administration in partially depancreatized rats. Diab. Res. Clin. Pract. 1995; 27, 51–59.
29. Mohammad S., Taha A., Bamezai R. N., Baquer N. Z. Modulation of glucose transporter (GLUT4) by vanadate and Trigonella in alloxan-diabetic rats. Life Sci. 2006; 78, 820–824.
30. Zhou J., Zhou S., Zeng S. Experimental diabetes treated with trigonelline: effect on ββ cell and pancreatic oxidative parameters. Fundam. Clin. Pharmacol. 2013; 27, 279–287.
31. Zhou J. Y., Zhou S. W. Protection of Trigonelline on Experimental Diabetic Peripheral Neuropathy. Evid. Based Complement. Alternat. Med. 2012; doi: 10.1155/2012/164219.
32. Joshi D. V., Patil R. R., Naik S. R. Hydroalcohol extract of Trigonella foenum-graecum seed attenuates markers of inflammation and oxidative stress while improving exocrine function in diabetic rats. Pharm. Biol. 2015; 53, 201–211.
33. Swaroop A., Bagchi M., Kumar P., Preuss H. G., Tiwari K., Marone P. A., Bagchi D. Safety, efficacy and toxicological evaluation of a novel, patented anti-diabetic extract of Trigonella Foenum-Graecum seed extract (Fenfuro). Toxicol. Mech. Methods 2014; 24, 495–503.
34. Koupý D., Kotolová H., Kučerová J. Současné fytoterapeutické možnosti v léčbě diabetes mellitus. Prakt. lékáren. 2014; 10, 229–232.
35. Fuller S., Stephens J. M. Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv. Nutr. 2015; 6, 189–197.
36. Sergent D., Wang Q., Sasaki N. A., Ouazzani J. Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties. Bioorg. Med. Chem. Let. 2008; 18, 4332–4335.
37. Neelakantan N., Narayanan M., de Souza R. J., van Dam R. M. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr. J. 2014; 13, 7.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2015 Issue 3
Most read in this issue
- Enhancing of drug bioavailability using liquisolid system formulation
- The quality of life of patients suffering from the osteoporosis
-
Pharmaceutical history of capuchin monastery in Prague-Hradčan
Part II. Capuchin balsam (Balsamum capucinorum) -
Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus
II. Fenugreek (Trigonella foenum-graecum)